New York Gov. Andrew Cuomo on Monday announced that trials would be starting in his state, most likely in New Rochelle, where a large number of cases were discovered and several people already have recovered.
The FDA unlocked the use of convalescent plasma-derived from the donated blood of people that have recovered from COVID-19 and which may contain helpful antibodies-as an investigational treatment for patients with severe cases of the disease. "And there have been tests that show when a person is injected with the antibody, that then stimulates and promotes the immune system against the disease". "If you knew that, you know who is now immune to the virus and could be sent back to work".More news: United Kingdom will have coronavirus testing kits ready in days, health official says
"Given the public health emergency that the expanding COVID-19 outbreak presents, while clinical trials are being conducted, FDA is facilitating access to COVID-19 convalescent plasma for use in patients with serious or immediately life-threatening COVID-19 infections", the statement said.
That process includes filing for a single-patient, emergency investigational new drug application, or eIND.
On March 23, the NY governor, Andrew Cuomo, said that "We think it shows promise" using convalescent plasma to help with the state's hospitalization response to the outbreak. However, these procedures are relatively safe, provided the blood is screened for viruses and other components that could cause further infection. "It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so". For now, the experimental treatment will be reserved for patients who are in dire condition and at risk of death.More news: Oil extends gains as optimism over USA stimulus lifts global markets
Dr Arturo Casadevall, an immunologist at Johns Hopkins University, Baltimore, has also advocated this method for over a month.
Only time will tell whether this treatment has the capability to help reduce the virus' impact.More news: Mobile launches its $15 5G plan ahead of the Sprint merger